Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

BioGaia® Osfortis® winner of the NutraIngredients Awards 2022

BioGaia

Postmenopausal women are at high risk of developing osteoporosis as the drop in oestrogen levels during menopause is directly linked to reduced bone mass. Therefore, many women seek preventative measures. Osfortis contains the patented probiotic strain L. reuteri ATCC PTA 6475, in combination with vitamin D, which contributes to the maintenance of normal bones.

Since 2016, the NutraIngredients Awards honour the best and brightest ingredients, finished products and innovations in nutrition and dietary supplements. This year, a new category was introduced - "Innovations in Women's Health Award", which recognizes innovators with the best ingredients or products to promote women's health.

Ewa Hudson, Director of Insights at Lumina Intelligence headed up the panel of judges, made up of industry experts. The motivation from the jury was:

"BioGaia Osfortis is a probiotic product that helps postmenopausal women stay healthy and active longer, and we are impressed by the strength of the clinical evidence showing the efficacy of L. reuteri in reducing bone loss".  

-        Osteopenia is a silent disease responsible for many fractures in the elderly population. We are very proud to be able to offer a totally natural probiotic product without side effects, proven to reduce bone loss in older women, as shown in the clinical study by Principal investigator, Professor Mattias Lorentzon, says Isabelle Ducellier, CEO of BioGaia.

Read more about: BioGaia Osfortis (https://www.biogaia.com/product-country/biogaia-osfortis-sweden/) (link)

Read more about: NutraIngredients Awards 2022 (https://nutraingredients-awards.com/live/en/page/brochure) (link)

Read more about: The clinical trial by Professor M. Lorentzon (https://www.biogaia.com/indication-area/stay-healthy/bone-health/) (link)

For more information, please contact:

Isabelle Ducellier, CEO

+46 8 555 293 00

Latest press releases from BioGaia

06.05.2022 Annual General Meeting of BioGaia

06.05.2022 Record date for share division (split) in BioGaia AB

06.05.2022 Interim report January - March 2022

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.